Erythropoietin Stimulating Agent Ineligibility in Myelodysplastic Syndromes

In an effort to promote higher quality patient care NCODA created the NCODA Positive Quality Intervention (PQI) as a peer-reviewed clinical guidance resource for healthcare providers. By providing Quality Standards and effective practices around a specific aspect of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet concise resource for managing patients receiving oral or IV oncolytics. This PQI in Action is a follow up to the Erythropoietin Stimulating Agent Ineligibility in Myelodysplastic Syndromes PQI and explores how the medically integrated teams at Florida Cancer Specialists and Massachusetts General Hospital North Shore Cancer Center incorporate PQIs as part of their daily workflow. This article will discuss how utilizing the Erythropoietin Stimulating Agent Ineligibility in Myelodysplastic Syndromes PQI elevates patient care.